Abacus Global shifts listing to NYSE
Abacus Global Management is transferring the listing of its Class A common stock and 9.875% Fixed Rate Senior Notes from Nasdaq to the New York Stock Exchange. Trading on the NYSE is expected to begin around December 30, 2025, under the new ticker symbols ABX for common stock and ABXL for the senior notes. This move is intended to align with Abacus' long-term growth strategy by accessing a deeper institutional investor base and increasing liquidity.
Abacus Global Management to transfer listings from Nasdaq to NYSE By Investing.com
Abacus Global Management, Inc. announced its decision to transfer its common stock and senior notes listings from the Nasdaq Capital Market to the New York Stock Exchange (NYSE). Trading on the NYSE is expected to begin on December 30, 2025, under new symbols. This move follows impressive financial results for Abacus Life Inc., a related entity, and highlights significant strategic activities for the company.
Abacus Global Management to transfer listing from Nasdaq to NYSE
Abacus Global Management, an alternative asset management firm, announced its decision to transfer its stock listing from Nasdaq to the New York Stock Exchange. The move, effective December 30, 2025, aims to enhance shareholder value, with the company's Class A common stock trading under "ABX" on the NYSE. The company has shown strong financial performance, with impressive revenue growth and adjusted net income increases reported in Q3 2025.
Squarepoint Ops LLC Acquires 201,490 Shares of Abacus Life, Inc. $ABL
Squarepoint Ops LLC significantly increased its stake in Abacus Life, Inc. (NASDAQ:ABL) by 1,264.1% in Q2, acquiring an additional 201,490 shares. This move brings their total holdings to 217,430 shares, valued at approximately $1.12 million, representing about 0.22% of the company. Abacus Life has received mixed analyst ratings, with a consensus of "Moderate Buy" and an average price target of $12.67, while experiencing a recent 2.9% dip in stock price.
Abacus Global Management Announces Transfer of Listing of its [Class A] Common Stock to the New York Stock Exchange with New Ticker Symbol 'ABX”
Abacus Global Management announced its decision to transfer the listing of its [Class A] common stock from Nasdaq to the New York Stock Exchange (NYSE), effective around December 30, 2025, under the new ticker "ABX." This strategic move aims to leverage NYSE's global reach and market liquidity to enhance long-term shareholder value. The company's 9.875% Fixed Rate Senior Notes will also transfer to the NYSE under the symbol "ABXL."
Abacus Global Management Announces Transfer of Listing of
Abacus Global Management announced its decision to transfer the listing of its Class A common stock and 9.875% Fixed Rate Senior Notes due 2028 from Nasdaq to the New York Stock Exchange (NYSE). The move is expected to take effect around December 30, 2025, with the common stock trading under the new ticker symbol "ABX" and the senior notes under "ABXL." CEO Jay Jackson stated that this strategic decision aims to leverage NYSE's global reach and market liquidity to enhance shareholder value.
Why this asset manager is moving its stock from Nasdaq to the NYSE
Abacus Global Management announced its decision to transfer the listing of its Class A common stock and 9.875% Fixed Rate Senior Notes due 2028 from Nasdaq to the New York Stock Exchange (NYSE), effective on or about December 30, 2025. The company will trade under the new ticker symbol "ABX" for its common stock and "ABXL" for its senior notes. This strategic move is aimed at leveraging NYSE's global reach, institutional investor base, and market liquidity for continued growth and enhanced shareholder value.
Grandeur Peak Global Advisors LLC Grows Position in Abacus Life, Inc. $ABL
Grandeur Peak Global Advisors LLC significantly increased its stake in Abacus Life, Inc. (NASDAQ:ABL) by 102.2% in the second quarter, bringing its total to 390,645 shares valued at approximately $2.01 million. This move is part of a broader trend of rising institutional interest, with other firms like Charles Schwab and CSM Advisors also increasing or initiating positions. Despite mixed analyst ratings, Abacus Life has a consensus "Moderate Buy" rating with a target price of $12.67, and recently surpassed quarterly EPS and revenue estimates while announcing an annual dividend.
Abacus Global Management, Inc.'s (NASDAQ:ABL) 30% Jump Shows Its Popularity With Investors
Abacus Global Management (NASDAQ: ABL) has seen a 30% increase in its share price recently, reflecting investor confidence despite a 19% drop over the last year. The company's high price-to-sales (P/S) ratio of 3.3x, compared to an industry average below 1.1x, is attributed to impressive revenue growth of 92% last year and a projected 26% growth for the next year, significantly outperforming the industry's 3.6% forecast. This strong performance and future outlook suggest that investors are willing to pay a premium for ABL's stock.
Abacus Sells $50 Million of Securitized Life Insurance Assets to Institutional Investors
Abacus Global Management successfully sold $50 million of securitized life insurance assets to institutional investors. This transaction, structured as an above investment-grade rated collateralized note, provides institutional investors, banks, and insurance companies with direct exposure to life insurance assets through an uncorrelated rated structure. The deal highlights strong institutional demand for longevity-based assets offering diversification and mitigating risks associated with individual life settlement assets.
Abacus Global Management, Inc. (NASDAQ: ABL) Under Investigation Following “Fake Revenue” Allegations; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
Abacus Global Management, Inc. (NASDAQ: ABL) is under investigation by Gibbs Mura following allegations of "fake revenue" stemming from a "life settlements accounting scheme." A report by Morpheus Research claims Abacus systematically undervalues death predictions to overstate assets, causing a 30% stock plummet. Investors impacted by this drop are urged to contact Gibbs Mura for a potential securities class action lawsuit.
Abacus Life Closes $150 Million Debt Financing Facility to Support Continued Growth
Abacus Life Inc. has successfully closed a $150 million debt financing facility led by Sagard and Värde Partners. This funding will support the company's long-term strategic objectives, meet inventory demand, and fuel continued growth without needing to raise incremental equity in the near future. The facility underscores confidence in Abacus Life's business model and its expansion into areas like wealth management and tech services using longevity data.
Abacus Global Management Responds to False Short Report – Revenues Consistent with 20-Year Track Record
Abacus Global Management issued a response to a "false and misleading short attack," asserting that its revenues and valuations are consistent with a 20-year track record of positive returns. The company highlighted realized gains of nearly 40% with a $126 million deployment of capital, stating its operations are highly regulated and audited. Abacus plans to provide a more detailed response and pursue legal remedies against those responsible for the claims.
Abacus Life, Inc. Secures $150 Million Debt Financing Facility to Enhance Strategic Growth
Abacus Life, Inc. has successfully secured a $150 million debt financing facility to bolster its strategic growth and operational flexibility. This funding, arranged by Sagard with significant participation from Värde Partners, provides capital to meet inventory demands and avoids the need for immediate equity raises. The company, an alternative asset manager specializing in longevity data, aims to use this facility to strengthen its market leadership and expand its innovative wealth management and technology services.
ABL DOWN 15%: Block & Leviton Investigating Abacus Global Management Inc. For Possible Securities Fraud; Investors Encouraged to Contact the Firm To Potentially Recover Losses
Block & Leviton is investigating Abacus Global Management, Inc. (Nasdaq: ABL) for potential securities law violations after its shares fell over 15% due to a report alleging fake revenue generation. The report by Morpheus Research claims Abacus uses aggressive "mark-to-model" accounting tied to its life settlements portfolio and undisclosed related-party transactions. Investors who have lost money are encouraged to contact Block & Leviton to learn about recovering their losses.
Abacus (NASDAQ: ABL) sells $50M life insurance note with mid-single-digit yield, rated
Abacus (NASDAQ: ABL) announced the sale of $50 million in securitized life insurance assets to institutional investors. The transaction, structured as an above investment-grade rated collateralized note with a mid-single-digit yield, closed on October 22, 2025. This initiative aims to provide institutional investors, banks, and insurance companies with direct, rated exposure to life insurance assets, offering diversification and reduced correlation to traditional markets.
$156B Life Benefits — Abacus Global Management Acquires AccuQuote to Expand Insurance Platform
Abacus Global Management (NASDAQ: ABL) has announced the acquisition of AccuQuote, an online life insurance brokerage. This strategic move adds AccuQuote's digital distribution capabilities to Abacus's wealth management and alternative asset platform, aiming to serve clients across their full lifecycle. AccuQuote boasts a significant track record, having served nearly 350,000 families, written $156 billion in life insurance policy benefits, and generated almost $340 million in lifetime premiums.
Abacus Global Management Acquires AccuQuote
Abacus Global Management has announced the acquisition of AccuQuote, an online life insurance brokerage company. This strategic move is expected to expand Abacus' financial services platform, allowing it to integrate wealth management with protection planning and serve clients through their entire lifecycle. The acquisition combines AccuQuote's digital distribution platform with Abacus' financial planning and alternative asset management solutions, aiming for incremental revenue growth and a more holistic client approach.
ABACUS (ABL) INVESTIGATION ALERT: Bragar Eagel & Squire,
Bragar Eagel & Squire, P.C. is investigating potential claims against Abacus Global Management, Inc. (NASDAQ:ABL) after a report alleged the company was manufacturing fake revenue. The investigation follows a significant drop in Abacus's stock price and concerns whether Abacus violated federal securities laws or engaged in unlawful business practices. The firm is encouraging affected shareholders to contact them to discuss their legal rights.
Key Life Expectancy Provider Shuts Down: Coventry Moves to Dismiss Abacus Lawsuit Citing First Amendment
Coventry First LLC and Alan H. Buerger have filed a Motion to Dismiss a lawsuit by Abacus Global Management (NASDAQ: ABL), arguing it attempts to suppress constitutionally protected debate. This motion is bolstered by the shutdown of Lapetus Solutions, Abacus's primary life expectancy provider. Coventry maintains that transparent discussion on life expectancy estimates and industry practices is crucial for investors and regulators in the life settlement market.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abacus Global Management, Inc.
Pomerantz LLP is investigating Abacus Global Management, Inc. (NASDAQ: ABL) for potential securities fraud. This investigation follows a Morpheus Research report alleging Abacus manipulated its profitability through questionable portfolio valuation and life expectancy calculation methodologies, leading to a significant drop in Abacus's stock price. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report – Hagens Berman
Abacus Global Management (ABL) shares have fallen over 36% in the past month due to damning reports from Morpheus Research, leading law firm Hagens Berman to launch an investigation. Morpheus, founded by former Hindenburg Research analysts, alleges Abacus manipulated its life settlements portfolio and made questionable life expectancy estimates. Hagens Berman is encouraging affected shareholders and those with relevant information to come forward as they investigate potential investor misleading.
Coventry Reveals Major Discrepancies in Abacus SEC Filings: Life Insurance Valuation Methods Under Scrutiny
Coventry alleges that Abacus Global Management's lawsuit is a diversionary tactic masking contradictions between Abacus's claims and its SEC filings regarding life insurance policy valuations. Coventry asserts that Abacus's minority-owned company, Lapetus, systematically underestimates life expectancies, negatively impacting investor returns, despite Abacus's lawsuit claiming it doesn't rely on these estimates for valuations. Coventry also denies any connection to Morpheus Research and stands by the integrity of its position against the lawsuit.
Piper Sandler lowers Abacus Life stock price target to $10 from $12
Piper Sandler has reduced its price target for Abacus Life Inc. (NASDAQ: ABL) to $10 from $12 but maintained an Overweight rating, viewing the recent stock downturn as a buying opportunity despite a decline driven by a short report and warrant exchange. The firm believes the short report lacks validity and expects solid Q2 2025 results and continued growth, highlighting strong profitability and a valuation of approximately 5 times earnings. Abacus Life has also filed a lawsuit against Coventry First LLC for spreading false information and recently announced a warrant exchange offer to simplify its capital structure.
Wolf Popper LLP Announces Investigation on Behalf of Abacus Global Management, Inc. Investors
Wolf Popper LLP has initiated an investigation into potential claims for purchasers of Abacus Global Management, Inc. common stock. This follows two short seller reports from Morpheus Research, which alleged that Abacus manipulated its portfolio valuation methodology, used questionable life expectancy calculations, and engaged in undisclosed related party dealings by insiders. The reports led to a significant drop in Abacus's stock price, prompting the investigation into potential investor claims.
Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report - Hagens Berman
Shares of Abacus Global Management, Inc. (ABL) have significantly declined following a second report from Morpheus Research, an investigative group with ties to Hindenburg Research, alleging manipulative accounting practices. Despite Abacus's denials and a share repurchase program, investor confidence remains low, prompting law firm Hagens Berman to launch an investigation into the company's financial disclosures and encourage affected shareholders to report their losses. The firm is also seeking information from whistleblowers.
Abacus Global Management Reports First Quarter 2025 Results
Abacus Global Management reported strong first quarter 2025 results, with total revenue more than doubling year-over-year to $44.1 million and Adjusted Net Income growing 158% to $17.3 million. The company's Longevity Funds attracted $122.8 million in capital inflows, and it is maintaining its full-year 2025 outlook for Adjusted net income of between $70 million and $78 million. These results demonstrate significant growth in both revenue and profitability, driven by acquisitions and increased capital inflows into their asset management business.
Abacus Global Management blends technology and tradition to transform the life insurance marketplace
Abacus Global Management, an alternative asset manager specializing in life settlements, announced plans to transfer its stock listing from Nasdaq to the NYSE under the new ticker "ABX" by December 30, 2025. The company recently paid its inaugural annual cash dividend of $0.20 per share, aligning with its capital allocation framework. Abacus has consistently delivered strong financial performance, reporting its tenth consecutive quarter of earnings and exceeding Wall Street expectations in Q1 2025.
Abacus Global Management transforms life insurance as an alternative asset class
Abacus Global Management is revolutionizing the perception of life insurance, shifting it from a mere safety net to a dynamic alternative asset class. The company has expanded its focus from educating individuals about policy values to becoming a global asset manager, originating and managing life insurance alongside innovative data and technology. This strategic evolution, marked by a recent rebrand and significant revenue growth, positions Abacus Global Management as a unique player in asset management, leveraging life insurance and health data as its core strength.
Abacus Global Management transforms life insurance as an alternative asset class
Abacus Global Management (NASDAQ:ABL) is redefining life insurance from a passive safety net into a dynamic alternative asset class. The company, which recently rebranded to reflect its expanded global presence and technology-driven services, leverages life insurance and health data to offer a diversified portfolio and financial planning. Utilizing AI, Abacus analyzes vast amounts of lifespan data to make accurate predictions, distinguishing itself as both an origination company and a market maker in this unique asset space.
Abacus Life to Announce Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
Abacus Life, Inc. will release its fourth quarter 2024 financial results after market close on Thursday, March 27, 2025. The company will also host a conference call on the same day at 5:00 PM Eastern Time to discuss these results. A webcast replay will be available on their investor relations website.
Abacus Life Completes the Rebranding of FCF Advisors with New ETF and Fee Reductions
Abacus Life, Inc. announced the rebranding of FCF Advisors to Abacus FCF Advisors, a subsidiary of ABL Wealth, emphasizing its leadership in free cash flow investing. The rebranding includes the launch of the Abacus FCF Small Cap Leaders ETF (ticker: ABLS) and fee reductions on all ETFs, with an 18-month fee waiver on several. This move marks a significant expansion for Abacus in providing lifespan-based financial advisory services and products.
Abacus Life completes acquisition of FCF Advisors
Abacus Life has completed its acquisition of FCF Advisors, a New York-based asset manager specializing in free cash flow-focused investment strategies. This acquisition adds approximately $850 million in assets under management to Abacus Life's portfolio, bringing its total managed assets to nearly $3 billion. The move aims to expand Abacus Life's ABL Wealth offerings and deliver comprehensive, lifespan-based financial advisory services.
Abacus Life Completes Acquisition of Carlisle Management Company S.C.A.
Abacus Life (NASDAQ: ABL) has completed the acquisition of Carlisle Management Company S.C.A., a Luxembourg-based investment fund manager specializing in life settlements with over $2 billion in assets under management. This acquisition significantly expands Abacus's ABL Wealth division and is a key step in its strategy to grow its global alternative asset-management offerings. Jose Garcia, Carlisle's CEO, will join Abacus Life's Executive Leadership Team.
Consolidation in life settlements management, as Abacus Life acquires Carlisle
Abacus Life, an alternative asset manager specializing in life settlements, has acquired Carlisle Management, a Luxembourg-based investment manager, for approximately $200 million. This acquisition significantly boosts Abacus Life's scale, adding Carlisle's $2 billion in assets under management and expanding its global presence and offerings to institutional investors. The move is expected to drive further consolidation and institutional interest in the niche life settlements asset class.
Abacus Life Begins Trading on Nasdaq Under New Ticker Symbol “ABL”
Abacus Life Inc. (NASDAQ: ABL) announced it has begun trading on Nasdaq under the ticker symbol "ABL" following its business combination with East Resources Acquisition Company. The company, a leading buyer of life insurance policies and alternative asset manager, aims to capitalize on growth opportunities in the life settlement industry, which it estimates to be a $200 billion annual market. Abacus's management team will participate in an opening bell ceremony at Nasdaq on July 13, 2023, to mark the public listing.
